TRAVERE THERAPEUTICS, INC. (TVTX)
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
📈 **POSITIVE** • High confidence analysis (89%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business